MEDA AB Company Profile
Meda is one of Europe's leading specialty pharma companies. Meda covers all of Europe via its subsidiaries in more than 20 European countries; it has 900 employees in marketing and sales. In other world markets, agents and other pharma companies market and sell Meda's pharmaceuticals. Specialisation occurs within marketing and market-adapted product development. A key part of its product flow is also created through partnerships, in-licensing, and product acquisitions. Meda's pan-European marketing organisation and its capacity for product registration and development, make the company an attractive partner for pharmaceutical out-licensers.
Location
Box 906
Solna
SE-170 09
Sweden
Contact
Phone: 46 8-630 19 00
Fax: 46 8-630 19 50
Email: info@meda.se
News Articles
Meda expands collaboration with India's Cipla on Dymista
Swedish drugmaker Meda (OMX: MEDA A) is broadening its collaboration with Indian pharmaceutical company Cipla, thereby expanding its exclusive rights to Dymista (azelastine and fluticasone nasal spray...
Meda's Zyclara approved in the EU
Sweden-based Meda (OMX: MEDA A) yesterday announced that the European Commission has granted marketing authorization for Zyclara (imiquimod 3.75% cream), a patented product for the treatment of actini...
Meda rumored to be M&A target of Sun Pharma
Meda rose the most in a year in trading after the WSJ reported the company is in talks to be acquired by Sun Pharmaceutical for almost $5 billion. Meda climbed 3.4 percent to 86.80 kronor, giving the...
BRIEF-Drug firm Meda expands collaboration with the Indian pharma Cipla
STOCKHOLM, June 5 (Reuters) - Meda : * Expands collaboration with the Indian pharmaceutical company Cipla * Says the extended partnership, Meda now have full coverage in all growth
MEDA AB (publ) NOTICE OF ANNUAL GENERAL MEETING 2013
Regulatory News: Notice is hereby given that the Annual General Meeting (AGM) of Meda AB, corporate ID 556427-2812, will be held at 5.00 PM on Tuesday, May 7, 2013, at Meda's headquarters at Piper...
UPDATE 2-Swedish drugmaker Meda says not in sale talks
* Statement comes after sources say India's Sun eyeing Meda
Jazz Pharma sells women's health business to Meda for $95 million
US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced a definitive agreement to sell its women's health business, which includes six products, to Sweden-based Meda (OMX: MEDA) for $95 milli...
UPDATE 3-Sweden's Meda sale talks founder on valuation - source
* Generic drugs sector busy with deals (Adds Meda announcement on Cipla)
Drugs and Medications
Contac cold and flu [Meda Consumer Healthcare Inc.]
DRUG FACTS
Rynatuss [Meda Pharmaceuticals Inc.]
Rynatuss Tablets IN-0717-16 Rev. 1/09
Rynatan [Meda Pharmaceuticals Inc.]
RYNATAN TabletsIN-0707-07 Rev. 1/09
Organidin [Meda Pharmaceuticals Inc.]
Professional Labeling Information and Directions for Use This product labeled for sale on prescription only. Organidin NR (guaifenesin) Tablets
Rynatan [Meda Pharmaceuticals Inc.]
RYNATAN Chewable Pediatric Tablets IN-0712-05 Rev. 1/09
PubMed Articles
Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells.
"Ecstasy" (3,4-methylenedioxymethamphetamine or MDMA) is a widely abused recreational drug, reported to produce neurotoxic effects, both in laboratory animals and in humans. MDMA metabolites can be ma...
Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes.
Background and purpose: 3,4-Methylenedioxymethamphetamine (MDMA or "ecstasy") is a worldwide major drug of abuse known to elicit neurotoxic effects. The mechanisms underlying the neurotoxic effects of...
Hepatic injury after 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) intoxications is highly unpredictable and does not seem to correlate with either dosage or frequency of use. The mechanisms invol...
Herbal formulations are getting popular throughout the world and commercialized extensively for various medicinal properties. WHO has emphasized the need for quality assurance of herbal products, incl...
Exploring a Multidimensional Approach to Impulsivity in Predicting College Student Gambling.
Impulsivity has been implicated as a contributing factor in the development of gambling problems among college students, but attempts to confirm this relation have been inconsistent. One explanation f...
Clinical Trials
None
Companies
Meda is one of Europe's leading specialty pharma companies. Meda covers all of Europe via its subsidiaries in more than 20 European countries; it has 900 employees in marketing and sales. In other wor...
Leerink Swann is a healthcare-focused investment banking firm that provides equity research, corporate finance, strategic advisory and asset management services for institutional,...
Adeona (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that hav...
BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc.
BioSanteâs corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and its c...
More Information about "MEDA AB" on BioPortfolio
We have published hundreds of MEDA AB news stories on BioPortfolio along with dozens of MEDA AB Clinical Trials and PubMed Articles about MEDA AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MEDA AB Companies in our database. You can also find out about relevant MEDA AB Drugs and Medications on this site too.
